AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05244525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine with Epinephrine
Description: Randomization will be performed prior to surgery and group designation will be placed within an opaque envelope in the patient's chart.The circulating nurse will prepare the pre-operative injection. Study patients will receive an injection containing a total volume of 20 mL of bupivacaine with epinephrine (0.3 mL epinephrine in 30 mL of 0.5% bupivacaine).The syringe will not be labeled, and the contents of the injection will not be disclosed to the surgeon to preserve blinding. The injection will be performed with an 18-gauge needle into the subacromial space via a posterior or lateral approach after positioning the patient in the beach chair position, but prior to prepping and draping.Throughout the case, the mean arterial pressure of the patient will be monitored. At the conclusion of the surgical procedure, the surgeon will rate visual clarity on a visual analog scale. Changes in pump pressure from the initial pressure of 35mmHg during the surgical procedure will also be recorded.
Study NCT06164431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273 tablet
Description: Participants receive ZSP1273 tablet orally.
Study NCT05244525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine alone
Description: Randomization will be performed prior to surgery and group designation will be placed within an opaque envelope in the patient's chart.The circulating nurse will prepare the pre-operative injection. Control patients will receive an injection containing 20mL of 0.5% bupivacaine alone.Throughout the case, the mean arterial pressure of the patient will be monitored. At the conclusion of the surgical procedure, the surgeon will rate visual clarity on a visual analog scale.Changes in pump pressure from the initial pressure of 35mmHg during the surgical procedure will also be recorded.
Study NCT06192511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Website and Video
Description: The website offers users the opportunity to choose to watch a 4-minute video or read relevant information about Newborn Screening and the Michigan BioTrust. If they choose to read, the website is designed to present information in an engaging manner, while providing optional voiceover. The video uses a mixture of live action shots and animation, all with voiceover. All materials are available in English, Spanish and Arabic.
Study NCT06164431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zsp1273 granules
Description: Participants receive ZSP1273 granules orally.
Study NCT06137300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urinary kallidinogenase for injection
Description: Urinary kallidinogenase 0.15PNA once daily for 7 days.
Study NCT06137300 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Guideline-prescribed medical therapy
Description: Guideline-prescribed medical therapy
Study NCT06024447 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Subgingival Instrumentation
Description: Subgingival Instrumentation will be performed in patients with Stage III and IV periodontitis.
Study NCT05658081 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kono-S group
Description: patients in this arm will receive stapled Kono-S anastomosis after bowel resection
Study NCT05658081 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Side-to-side group
Description: patients in this arm will receive stapled antimesenteric isoperistaltic side-to-side anastomosis after bowel resection
Study NCT06439511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Darwin smartphone app
Description: The participant must look into the smartphone camera with the Darwin app for about 30 seconds.
Study NCT06439511 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulse oxymetry
Description: Heart rate will be measured with pulsoe oximetry (gold standard)
Study NCT06584708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-volume high intensity interval training
Description: Week 1 \& 2:~Warm-up: 10 minutes at 50% THR Work: 1x4 minutes at 80% THR followed by 1\*4 minutes Recovery at 50% THR Cool down: 5 minutes at 50% THR Total exercise time: 23 minutes~Week 3 \& 4:~Warm-up: 10 minutes at 50% THR Work: 2x6 minutes at 80% THR followed by 1\*6 minutes Recovery at 50% THR Cool down: 5 minutes at 50% THR Total exercise time: 33 minutes
Study NCT06584708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate intensity continuous exercise
Description: Week 1 \& 2:~Warm-up: 5 minutes at 50% THR Work: 20 minutes at 60% VO 2 THR Cool Down: 5 minutes at 50% THR Total exercise time: 30 minutes~Week 3 \& 4:~Warm-up: 5 minutes at 50% THR Work: 30 minutes at 60% THR Cool Down: 5 minutes at 50% THR Total exercise time: 40 minutes
Study NCT06314074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oscillometric blood pressure monitoring at 2.5-minute intervals
Description: Oscillometric blood pressure will be measured at 2.5-minute intervals during surgery.
Study NCT06314074 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oscillometric blood pressure monitoring at 5-minute intervals
Description: Oscillometric blood pressure will be measured at 5-minute intervals during surgery.
Study NCT04335292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib First-Line
Description: Osimertinib, 80 mg, oral, daily
Study NCT04335292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum + Pemetrexed Chemotherapy Second-Line
Description: Platinum-based chemotherapy (carboplatin or cisplatin) and pemetrexed are prescribed as per institutional standards.
Study NCT04335292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib Third-Line
Description: Rechallenge with osimertinib, 80 mg, oral, daily
Study NCT05673018 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-Cancer Early Detection Test (Galleri®)
Description: Blood collection and multi-cancer early detection testing with return of results.
Study NCT05361798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M9241
Description: In the safety lead in, M9241 will be given in de-escalating doses (starting dose 16.8 mcg/kg, and de-escalated if needed to 12 mcg/kg, or 8 mcg/kg) every 4 weeks for 3 doses. Within 4 weeks after completing SBRT, those participants receiving immunotherapy agents will receive M9241 by subcutaneous injection at dose determined during the safety lead in every 4 weeks for 3 doses.
Study NCT05361798 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: SBRT to the prostate will be delivered in 5 fractions of radiation each of 7.25-8.0 Gy, every other day over the course of 10 business days (2-3 weeks). The total dose will be 36.25-40 Gy
Study NCT06576752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital follow-up and uptitration of medications at home after hospital discharge for heart failure
Description: Both arms will treat the patients according to the STRONG-HF intensive care strategy, as recommended by current guidelines. That is up-titration to at least half of maximum tolerated doses of HF medications at discharge, followed by up-titration to maximum tolerated doses after 2 weeks. Safety visits will be performed after 1, 3 and 6 weeks.
Study NCT06576752 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up and uptitration of medications at the hospital outpatient-clinic after hospital discharge for heart failure
Description: Both arms will treat the patients according to the STRONG-HF intensive care strategy, as recommended by current guidelines. That is up-titration to at least half of maximum tolerated doses of HF medications at discharge, followed by up-titration to maximum tolerated doses after 2 weeks. Safety visits will be performed after 1, 3 and 6 weeks.
Study NCT05461248 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stoma drainage reinfusion
Description: 1 month after radical rectal surgery, the stoma drainage fluid was reinfused once a week for 2 months. For each reinfusion, eat liquid food the day before, collect 400-600mL of stoma discharge on the same day (if the stoma fluid is too small, it can be mixed with warm water), and use an enema bag to reinfuse from the patient's anus. Generally, the flow rate is controlled at about 100mL/min.
Study NCT05461248 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Standard of Care - No Return of Stoma Drain
Description: No Return of Stoma Drain
Study NCT06446193 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NDTx-01
Description: NDTx-01 intervention: Run 'NDTx-01' application on a smartphone 5 times a week, for 6 weeks, 30 sessions in total.
Study NCT06446193 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: TAU
Description: TAU: Autism Spectrum Disorders(ASD) or Social Communication Disorders(SCD)-related treatment/rehabilitation/education
Study NCT06446193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU
Description: TAU: Autism Spectrum Disorders(ASD) or Social Communication Disorders(SCD)-related treatment/rehabilitation/education
Study NCT06650072 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified coronally advanced tunnel technique combined with multiple palatal micro connective tissue grafts
Description: The connective tissue graft will be harvested from the palate.
Study NCT06650072 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified coronally advanced tunnel technique combined with multiple tuberosity micro connective tissue grafts
Description: The connective tissue graft will be harvested from the maxillary tuberosity.
Study NCT06650683 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pediatric HAH
Description: Pediatric HAH nursing support for home nursery care provided by parents as part of their child's disease.
Study NCT05780515 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANX009
Description: ANX009 will be administered per schedule specified in the arm description.
Study NCT05248425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse Monitoring
Description: Questionnaire responses that indicate new or worsening symptoms will be monitored by a study nurse who will contact the participant for clinical assessment and develop a management plan following irAEs management guidelines.
Study NCT05807542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab will be administered on day 1 of each cycle at 200mg once every 21 days.
Study NCT05807542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel-albumin
Description: Paclitaxel-albumin will be administered on day 1 of each cycle at 260mg/m2 once every 21 days.
Study NCT05807542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin will be administered on day 1 of each cycle at AUC=5 once every 21 days.
Study NCT06301542 — intervention group
Intervention type: DEVICE
Intervention: Functional electrical stimulation
Description: The FES system will be placed on the plantar flexors, dorsiflexion, and quadriceps muscles and be paired with the machine learning directed inertial measurement units.
Study NCT05454319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: Home-based biofeedback with medical device
Study NCT06525350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glumetinib tablets
Description: An ATP competitive, highly selective MET receptor tyrosine kinase inhibitor
Study NCT05024812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fruquintinib＋toripalimab + SOX
Description: phase Ib: fruquintinib (dose finding): L1: 3 mg/d，L2: 4 mg/d，L3: 5 mg/d, qd po, D1-14, Q3W toripalimab: 240mg, I.V., D1, Q3W; S-1: 40-60mg bid, D1-14, Q3W; Oxaliplatin: 130mg/m\^2, ivgtt 2h, D1,Q3W. phase II: fruquintinib: RP2D toripalimab: 240mg, I.V., D1, Q3W; S-1: 40-60mg bid, D1-14, Q3W; Oxaliplatin: 130mg/m\^2, ivgtt 2h, D1,Q3W.
Study NCT06222996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: vaccine hesitation training
Description: Training will be given to primiparous expectant mothers on vaccine hesitation with the support of the web page created by the researcher
Study NCT05887518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Socks Developed with Wearable Technology
Description: This new material will have the ability to prevent hypothermia by rewarming the patient when the body temperature drops below 360C and will reduce the risk of DVT that may develop in patients due to hypothermia. Thus, a single material will be used for two important complications of the surgical process, such as hypothermia and DVT, which negatively affect patient outcomes. This situation suggests that this material developed with an innovative approach will be more cost effective.
Study NCT05927207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TRIP
Description: TRIP is a mobile app-based intervention for supporting and empowering parents of children with autism spectrum disorder (ASD), comprises of a 6-week structured training on mindfulness and educational modules on ASD parenting skills.
Study NCT06061848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SLIT Grazax ALK Nordic 75 000 SQ-T
Description: Daily sublingual grass allergen tablets
Study NCT06061848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ILIT + Vitamin D
Description: 1 mL of Vicotrat D3, Heyl Pharma, 100 000 IU/mL, as intramuscular injection. Followed by 0,1 mL of Alutard SQ timothy, ALK Nordic, 10 000 SQ-U/mL as three intralymphatic injections
Study NCT06061848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ILIT + placebo
Description: 1 ml of Sodium chloride solution 9 mg/mL as intramuscular injection followed by 0,1 mL of Alutard SQ timothy, ALK Nordic, 10 000 SQ-U/mL as three intralymphatic injections
Study NCT05847569 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Belantamab Mafodotin
Description: Given IV
Study NCT05847569 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belantamab Mafodotin
Description: Given IV
Study NCT05847569 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT05847569 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT05790343 — intervention group
Intervention type: BEHAVIORAL
Intervention: BAPHYC
Description: Nine weekly peer led group meetings
Study NCT06440525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RSLV-132
Description: Fc fusion protein comprised of catalytically active human ribonuclease (RNase) fused to human immunoglobulin G1 (IgG1)
Study NCT06440525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride solution
Study NCT06657274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RICORDO-DTx
Description: Tele@cognitive treatment group will receive a total of 5 weeks (3 sessions/week, 45 minutes/session) of home-based cognitive rehabilitation activities with an innovative digital solution for remote rehabilitation of cognitive difficulties according to digital therapeutics delivery model. Subjects assigned to the tele@cognitive group can access the app RICORDO-DTx through a tablet showing the prescribed rehabilitation activities to be performed.~Each cognitive exercise is structured into five levels of difficulty that adaptively increase (algorithm on both subject's performance and perceived difficulty). All data about patient progress and adherence will be collected with this digital solution and will be available to evaluate and monitor the results of rehabilitation.
Study NCT06657274 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-based unstructured cognitive stimulation
Description: Subjects assigned to the home-based unstructured cognitive stimulation will be requested to work on detailed activities for the same duration of the tele@cognitive intervention (3 sessions/week, 45 minutes/session). They will receive, from the therapist, an instructions booklet and a participant diary.
Study NCT05638360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ru Yi Jin Huang Powder
Description: Each patch contains 13g Ru Yi Jin Huang Powder and 10c.c. water.
Study NCT05638360 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each patch contains 13g starch and 10c.c. water.
Study NCT05847569 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspirate
Description: Undergo bone marrow aspirate
Study NCT05847569 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate
Description: Undergo bone marrow aspirate
Study NCT05847569 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Biopsy
Description: Undergo biopsy
Study NCT05847569 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo biopsy
Study NCT05847569 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT05847569 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT05847569 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI scan
Study NCT05847569 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI scan
Study NCT05847569 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan
Study NCT05847569 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan
Study NCT05390853 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: tDCS application is anodic, in the M1 area (Primary Motor Cortex) right or left, contralateral to the pre-defined target limb. The cathode is positioned in the supraorbital area, contralateral to the anode.~Active stimulation is carried out with a current intensity of 2 milliAmpere. Each tDCS session lasts 20 minutes. tDCS is administered simultaneously during the first 20 minutes of the usual upper limb rehabilitation physiotherapy, which will continue for a further 20 minutes.~During the whole study period (10 weeks) each patient is not subjected to any focal treatments in the target upper limb.~In the study period, the contralateral limb is rehabilitated and evaluated according to usual practice.
Study NCT05390853 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tDCS
Description: tDCS application is anodic, in the M1 area (Primary Motor Cortex) right or left, contralateral to the pre-defined target limb. The cathode is positioned in the supraorbital area, contralateral to the anode.~Sham stimulation is carried out through a dedicated program, which increases the current for several seconds up to the target intensity and then decreases it gradually in a few seconds, so that subjects experience the same itching and tingling experience as in active stimulation, but they do not receive any significant therapeutic currents.~Each tDCS session lasts 20 minutes. tDCS is administered simultaneously during the first 20 minutes of the usual upper limb rehabilitation physiotherapy, which will continue for a further 20 minutes.~During the whole study period (10 weeks) each patient is not subjected to any focal treatments in the target upper limb.~In the study period, the contralateral limb is rehabilitated and evaluated according to usual practice.
Study NCT04969263 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine (Pfizer/BioNTech)
Description: 30 microgram dose
Study NCT04969263 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273 vaccine (Moderna)
Description: 100 microgram dose
Study NCT04677907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Persona (Zimmer) posterior stabilised uncemented Trabecular Metal™ (Tibia and Femur) prosthesis
Description: Persona (Zimmer) posterior stabilised uncemented Trabecular Metal™ (Tibia and Femur) prosthesis vs a Persona (Zimmer) posterior stabilised cemented prosthesis
Study NCT04677907 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Persona (Zimmer) posterior stabilised cemented Trabecular Metal™ (Tibia and Femur) prosthesis
Description: Persona (Zimmer) posterior stabilised uncemented Trabecular Metal™ (Tibia and Femur) prosthesis vs a Persona (Zimmer) posterior stabilised cemented prosthesis
Study NCT06540833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-1284
Description: ITI-1284 10 mg or 20 mg rapidly disintegrating tablet, taken once daily, sublingual administration
Study NCT06540833 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo rapidly disintegrating tablet, taken once daily, sublingual administration
Study NCT06525350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB1801 (docetaxel, albumin-bound）
Description: An improved new formulations of docetaxel
Study NCT06525350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: A chemotherapy drug